Document:

EX-10.2

 Exhibit 10.2 

Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly
disclosed. 
 EXECUTION VERSION 

MICROSOFT ARTIFICIAL INTELLIGENCE & RESEARCH GROUP 

STRATEGIC COLLABORATION AGREEMENT 
 This
Strategic Collaboration Agreement (this “Agreement”) is made and entered into as of the last signature date written below (the “Effective Date”) by and between Microsoft Corporation, a Washington corporation having
its principal place of business at One Microsoft Way, Redmond, Washington, USA 98052 (“Microsoft“) and Adaptive Biotechnologies Corporation, a company having its principal place of business at 1551 Eastlake Ave E, Seattle, WA 98102
(“Adaptive”). Microsoft and Adaptive are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties.” 

BACKGROUND 
  

	A.	 Adaptive is a biotechnology industry pioneer and leader that focuses on combining high-throughput
sequencing and expert bioinformatics capabilities to profile T-cell and B-cell receptors. Adaptive owns or has access to data that can be used to computationally derive T-cell receptor-antigen mappings. 

  

	B.	 Microsoft is a worldwide technology company that develops, sells and otherwise makes available a wide
variety of software applications, cloud services, machine learning technologies, and other products that affect the life sciences and healthcare industries. 

  

	C.	 Adaptive and Microsoft desire to set forth the terms on which they intend to pursue their shared goal of
computationally deriving T-cell receptor (“TCR”) to antigen mappings in order to create a comprehensive map for purposes of developing biological research, diagnostic or therapeutic
applications (the “Project”). The Parties’ vision is that their collaboration will ultimately enable them to develop a universal diagnostic based on a single blood draw and TCR sequencing. 

 

	D.	 To pursue the goals described above, Microsoft intends to provide reasonable machine learning, software
and cloud services development support, including making Microsoft Research personnel with computational and machine learning domain expertise reasonably available to work with Adaptive on the collaboration project, and to develop the Immunomics AI
Services (as defined in this Agreement), at no charge to Adaptive, in order to carry out activities under the Development Plan (as defined in this Agreement). 

 

	E.	 To pursue the goals described above, Adaptive intends to provide data and immunomics, diagnostic and
bioinformatics expertise, at no charge to Microsoft, in order to carry out activities under the Development Plan. 

  

	F.	 Adaptive also intends, after a reasonable transition period and subject to the further terms and
conditions set forth in this Agreement, to use Microsoft’s Azure cloud services to host all of its existing and new activities that are hosted on a public cloud service. Adaptive and Microsoft are entering into a commercial agreement regarding
Adaptive’s use of Azure concurrently with this Agreement. 

  
 Confidential 

1 

 AGREEMENT 

In consideration of the terms of this Agreement and other good and valuable consideration, the sufficiency of which is acknowledged, the Parties agree as
follows: 
 1.    DEFINITIONS. The definitions of terms used in initially capitalized form in this Agreement are set forth
in Exhibit A or elsewhere in this Agreement. 
 2.    DEVELOPMENT EFFORT. 

2.1    Development Plan. The Parties have mutually agreed on the initial Development Plan incorporated in this Agreement as
Exhibit B. The Parties’ Project Managers will review the Development Plan periodically, and upon mutual written agreement of the Parties’ Relationship Managers, the Parties may update the Development Plan to reflect the evolution of
activities under the then-current Development Plan and add details regarding upcoming activities they intend to carry out under the Collaboration; provided, however, that in the event any such update to the Development Plan has the effect of
amending, modifying or supplementing the terms of this Agreement, such update to the Development Plan must be approved in accordance with Section 12.12. 

2.2    Good Faith Efforts to Carry Out Development Plan. The Parties will act in good faith during the Development Term to
carry out the activities described in the Development Plan in accordance with the timelines it sets forth. Without limiting the foregoing, each Party will act in good faith to develop, procure and make available the technologies, data and/or other
project components for which it is responsible under the Development Plan. 
 3.    PROJECT MANAGEMENT AND RELATIONSHIP
MANAGEMENT 
 3.1    Project Management. Each Party will designate an individual to act as its project manager
(“Project Manager”) with respect to the Collaboration and coordinate that Party’s activities under the Development Plan. The Parties’ Project Managers will schedule and conduct regular meetings to discuss the status of the
activities under the Development Plan. Without limiting the foregoing, the Project Managers will: 
 (a)    review the
Development Plan at least once every calendar quarter during the Development Term, and more frequently if requested by either Party; 

(b)    recommend changes in the Development Plan as may be desirable to reflect any changes in the scope, objectives,
tasks, responsibilities of each Party, schedule, or other aspects of the Collaboration; 
 (c)    coordinate the review
and approval process regarding any publicity activities, publications or other communications regarding the Collaboration; and 

(d)    prepare written reports on the status of activities under the Development Plan for review by the Relationship
Managers at least once during each calendar quarter and more frequently if requested by either Party. 

  
 Confidential 

2 

 3.2.    Relationship Management. Each Party will designate an individual
to serve as that Party’s overall relationship manager for purposes of the Collaboration (each, a “Relationship Manager”). As of the Effective Date, the Relationship Managers are the individuals designated to perform such role
in Exhibit C. Either Party may replace its Relationship Manager upon written notice to the other Party. 
 3.3    GTM
Discussions. The Relationship Managers will meet at least twice per calendar year during the Development Term, or as otherwise mutually agreed, to discuss go to market (“GTM”) strategies applicable to products or services that
result from the Collaboration. Adaptive will provide Microsoft with information about GTM strategies that Adaptive is considering in advance of execution of such strategies and will provide Microsoft an equitable opportunity to provide input to and
participate in the development and execution of such GTM strategies; provided, however, that Adaptive will have the sole and exclusive right to make final determinations regarding GTM strategies. For clarity, the foregoing proviso does not modify or
supersede any of the license terms or conditions set forth in this Agreement. 
 3.4    Dispute Resolution. The Parties will
endeavor to resolve any dispute that arises under this Agreement by using the escalation procedures set forth in Exhibit C, subject to the exceptions described in Exhibit C. 

4.    OWNERSHIP OF PROJECT MATERIALS, COLLABORATION OUTPUTS AND RELATED PROPRIETARY RIGHTS 

4.1    Project Materials and Background Rights. Each Party owns and will retain all ownership rights in all Project
Materials such Party uses or makes available for use in the Collaboration. Each Party also owns and will retain all ownership rights in such Party’s Background Non-Patent IP and Background Inventions.

 4.2    Outputs of the Collaboration. 

(a)    Adaptive will own (i) all Adaptive’s Outputs, (ii) all Foreground
Non-Patent IP embodied or implemented in Adaptive’s Outputs, (iii) all Adaptive Foreground Inventions, and (iv) all Joint Foreground Inventions and Microsoft Foreground Inventions that (in each
case) read on Adaptive’s Outputs or Microsoft’s Outputs. 
 (b)    Microsoft will own (i) all
Microsoft’s Outputs, and (ii) all Foreground Non-Patent IP embodied or implemented in Microsoft’s Outputs. 

4.3    Assignments of Rights. 

(a)    Pursuant to Section 4.2(a), Microsoft hereby assigns and agrees to assign to Adaptive (i) all of
Microsoft’s rights in any Foreground Non-Patent IP embodied or implemented in Adaptive’s Outputs, (ii) all Microsoft Foreground Inventions that read on Adaptive’s Outputs or
Microsoft’s Outputs, and (iii) all Microsoft Patent Rights in Joint Foreground Inventions that read on Adaptive’s Outputs or Microsoft’s Outputs. 

(b)    Pursuant to Section 4.2(b), Adaptive hereby assigns and agrees to assign to Microsoft all of Adaptive’s
rights in any Foreground Non-Patent IP embodied or implemented in Microsoft’s Outputs. 

(c)    Each Party will take all necessary steps, at such Party’s expense, to execute and deliver any instruments and
take any other actions reasonably requested by the other Party to perfect the assignments of Non-Patent IP and Patent Rights contemplated by Sections 4.3(a) and (b), as applicable. 

  
 Confidential 

3 

 (d)    For clarity, the assignments contemplated by this
Section 4.3 are limited to the Foreground Non-Patent IP and Foreground Patent Rights expressly specified in Sections 4.3(a) and (b), as applicable. Assignments under this Section 4.3 do not and will
not include any other Non-Patent IP or Patent Rights of the assigning Party, including without limitation in such Party’s Background Non-Patent IP and Background
Inventions, even if these are included in or necessary for the assignee’s exploitation of Microsoft’s Outputs or Adaptive’s Outputs, as applicable. 

(e)    Adaptive will be responsible for, and will have the sole and exclusive right to make final determinations regarding,
the maintenance and prosecution of Microsoft Foreground Inventions and Joint Foreground Inventions assigned to Adaptive under Section 4.3(a), but Adaptive will consider Microsoft’s input regarding such maintenance and prosecution
activities. Microsoft will provide such non-monetary assistance as Adaptive may reasonably request in connection with Adaptive’s preparing, filing, and prosecuting applications for Microsoft Foreground
Inventions and Joint Foreground Inventions assigned to it under Section 4.3(a). 
 (f)    Neither Party will
transfer to or grant to any Third Party any ownership of or rights or licenses in any Foreground Inventions or Foreground Non-Patent IP owned by that Party that prevent the other Party from practicing license
rights granted to it under this Agreement or interfere with the other Party’s ability to fully exercise any such license rights. 

5.    LICENSE GRANTS 

5.1    Development Plan Activities. Each Party hereby grants to the other Party a
non-exclusive, non-sublicensable, non-transferable (except as set forth in Section 12.2), worldwide, royalty-free, fully
paid license under all of the granting Party’s Non-Patent IP and Patent Rights to exercise all rights necessary to carry activities under the Development Plan during the Development Term. 

5.2    Microsoft Licenses to Adaptive. Microsoft hereby grants to Adaptive: 

(a)    (i) An exclusive, perpetual, non-transferable (except as set forth in
Section 12.2), irrevocable, worldwide, royalty free, full paid license, under Microsoft’s Foreground Non-Patent IP, for Adaptive’s internal research and development and to Commercialize
Adaptive’s Outputs and Adaptive Offerings that use the Immunomics AI Services, all solely within the Field of Use; (ii) an exclusive, perpetual, non-transferable (except as set forth in
Section 12.2), irrevocable, worldwide, royalty free, full paid license, under Microsoft’s Foreground Non-Patent IP, for Adaptive’s internal research and development and to Commercialize
Adaptive’s Outputs and Adaptive Offerings that use Algorithms, all solely within the Project; and (iii) a non-exclusive, perpetual, non-transferable (except as
set forth in Section 12.2), irrevocable, worldwide, royalty free, full paid license, under Microsoft’s Foreground Non-Patent IP, for Adaptive’s internal research and development and to
Commercialize Adaptive’s Outputs and Adaptive Offerings that use Algorithms, all solely within the Field of Use outside of the Project; 

(b)    A non-exclusive, perpetual,
non-transferable (except as set forth in Section 12.2), irrevocable, worldwide, royalty free, fully paid license, under Microsoft’s Background Non-Patent IP,
for Adaptive’s internal research and development and to Commercialize Adaptive’s Outputs and Adaptive Offerings that use Microsoft’s Outputs, all solely within the Field of Use; and 

(c)    A non-exclusive, perpetual,
non-transferable (except as set forth in Section 12.2), irrevocable, worldwide, royalty free, fully paid license, under Microsoft’s Background Inventions that are necessarily infringed by
Microsoft’s Outputs, for Adaptive’s internal research and development and to Sell Adaptive’s Outputs and Adaptive Offerings that use Microsoft’s Outputs, all solely within the Field of Use. 

  
 Confidential 

4 

 5.3    Adaptive Licenses to Microsoft. Adaptive hereby grants to Microsoft
and its Affiliates: 
 (a)    An exclusive, perpetual, non-transferable (except
as set forth in Section 12.2), irrevocable, worldwide, royalty free, fully paid license, under Adaptive’s Foreground Non-Patent IP, to Commercialize Microsoft’s Outputs as part of any and all
Microsoft Offerings, all solely outside the Field of Use; 
 (b)    (i) An exclusive, perpetual, non-transferable (except as set forth in Section 12.2), irrevocable, worldwide, royalty free, fully paid license, under Adaptive Foreground Inventions, Joint Foreground Inventions and Microsoft Foreground
Inventions, to Sell Microsoft’s Outputs as part of any and all Microsoft Offerings, all solely outside the Field of Use; and (ii) a non-exclusive, perpetual, nontransferable (except as set forth in
Section 12.2), irrevocable, worldwide, royalty free, fully paid license, under Adaptive Foreground Inventions, Joint Foreground Inventions and Microsoft Foreground Inventions, to Sell Algorithms as part of any and all Microsoft Offerings, all
solely within the Field of Use outside the Project. 
 (c)    A non-exclusive,
perpetual, non-transferable (except as set forth in Section 12.2), irrevocable, worldwide, royalty free, fully paid license, under Adaptive’s Background
Non-Patent IP, to Commercialize Microsoft Outputs as part of any and all Microsoft Offerings, all solely outside the Field of Use; 

(d)    A non-exclusive, perpetual,
non-transferable (except as set forth in Section 12.2), irrevocable, worldwide, royalty free, fully paid license, under Adaptive Background Inventions that are necessarily infringed by Microsoft’s
Outputs, to Sell Microsoft Outputs as part of any and all Microsoft Offerings, all solely outside the Field of Use; and 

(e)    A non-exclusive, perpetual,
non-transferable (except as set forth in Section 12.2), irrevocable, worldwide, royalty free, fully paid license, under all Joint Foreground Inventions and Microsoft Foreground Inventions, for
Microsoft’s internal research purposes only (including research within the Field of Use); provided, however, that such internal research may not be conducted in collaboration with any Third Party on any research substantially similar to the
Project or used to assist any Third Party Commercialization of any Offerings for purposes or with the effect of circumventing Adaptive’s rights under Sections 4 and 5 or in any manner that would not comply with Section 6.5; and provided
further that following the Development Term, the foregoing license may not be used by Microsoft for research substantially similar to the Project. 

5.4    Modified and New License Grants Arising from Certain Circumstances. Upon consummation of a Corporate Event in which
[***] or any Affiliate of the foregoing is the counter-party: 
 (a)    the exclusive licenses granted by Microsoft under
Section 5.2(a)(i) and (ii) will automatically become non-exclusive (and, for clarity, this license will remain limited to the Field of Use); 

(b)    Adaptive will automatically be deemed to grant to Microsoft and its Affiliates a nonexclusive, perpetual, non-transferable (except as set forth in Section 12.2), irrevocable, worldwide, fully paid, royalty free, fully paid up, license (i) under Adaptive’s Foreground
Non-Patent IP and Adaptive’s Background Non-Patent IP, to Commercialize the Computational Models as part of any and all Microsoft Offerings (i.e., whether or not in
the Field of Use), and (ii) under Adaptive Foreground Inventions, Joint Foreground Inventions, Microsoft Foreground Inventions, and Adaptive Background Inventions, to Sell the Computational Models as part of any and all Microsoft Offerings
(i.e., whether or not in the Field of Use); and 
 (c)    The limitations regarding Microsoft research activities after
the Development Term in the final clause of Section 5.3(e) will no longer apply. 

  
 Confidential 

5 
 Certain information, as identified by
[***], has been excluded from this agreement because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

 5.5    Enforcement Rights under Exclusive Licenses. The exclusive
licenses granted to each Party under this Agreement will provide the licensed Party with an exclusive right to enforce the licensed rights within the scope of its exclusive licenses against infringers at its own cost and expense, and the Party that
is the licensor agrees to join enforcement actions (at the licensed Party’s expense) if the licensor Party is a necessary party to bring such an action. 

5.6    Protection of Licenses in Bankruptcy. The Non-Patent IP and Patent
Rights referenced in Section 4 are intellectual property, and the licenses granted in this Section 5 are licenses to intellectual property, under the Bankruptcy Law. In the event of any proceeding for the bankruptcy, reorganization, or
protection of either Party or any of their Affiliates under any applicable Bankruptcy Law, the licenses granted under this Section 5 will be subject to Section 365(n) of the United States Bankruptcy Code and any corresponding or similar
provision for the protection of licensees of intellectual property under any other Bankruptcy Laws. If any debtor-in-possession, trustee, or similar authority rejects,
cancels, or similarly acts with respect to this Agreement under any applicable Bankruptcy Law, the licensed Party may elect to retain its rights under the applicable license terms in this Section 5 as provided for in Section 365(n) of the
United States Bankruptcy Code or any corresponding or similar provision under any other applicable Bankruptcy Law. 

5.7    Reservations of Rights. Except to the extent expressly set forth in this Agreement, this Agreement does not assign,
grant or otherwise transfer, whether by implication, estoppel or otherwise, any license or other right in, to or under any Non-Patent IP or Patent Rights of either Party. All rights not expressly granted in
this Agreement are reserved. Without limiting the generality of the foregoing: 
 (a)    except for the licenses in
Section 5, and the assignments in Section 4, each Party reserves all of its right, title and interest in and to its Project Materials, Non-Patent IP and Patent Rights; 

(b)    Nothing contained in this Agreement will be construed as: 

(i)    a warranty or representation by either Party as to the validity, enforceability, and/or scope of any
Patent Rights or Non-Patent IP; or 
 (ii)    imposing upon
either Party any obligation to institute any suit or action for infringement of any Patent or Non-Patent IP, or to defend any suit or action brought by a Third Party against such Party which challenges or
concerns the validity, enforceability, or scope of any Patent or Non-Patent IP; and 

(c)    except as may be expressly agreed upon by the Parties with respect to any press release or other publicity
activities conducted pursuant to Section 7.3, neither Party grants any license or other right in or to any of its Trademarks under this Agreement, and neither Party will use any Trademark of the other Party in any publicity, advertising or
other promotional activities without the prior written consent of such other Party, provided that the foregoing does not restrict any right that either Party may have under Applicable Laws to make accurate, descriptive and nominative references to
the other Party’s Trademarks. 
 6.    EXCLUSIVITY AND CLOUD SERVICES COMMITMENTS 

6.1    Azure Commercial Agreement. Following the Parties’ entry into this Agreement, Microsoft and Adaptive plan to
enter into separate commercial agreements regarding Adaptive’s purchase of Azure Services (the “Commercial Agreement”), which include standard volume pricing terms and a minimum Azure consumption requirement. Nothing in this
Agreement will be deemed to modify or supersede the terms of the Commercial Agreement. 

  
 Confidential 

6 

 6.2    Exclusive Use of Azure. Adaptive agrees that throughout the
Development Term and, if longer, until the seven (7) year anniversary of the Effective Date, all Collaboration activities that use a cloud service (including the Immunomics AI Services) will use Azure exclusively, subject to Adaptive’s
right to terminate the Commercial Agreement for breach or non-performance as set forth in the Commercial Agreement. In addition, Adaptive agrees to ensure that on a reasonably expedient schedule, and in any
event within no more than eighteen (18) months after the Effective Date, all activities for which Adaptive uses any cloud (or “hosted”) service, including both new and ongoing Adaptive activities that use a cloud service (regardless
of whether such activities are related to the Collaboration), will use Azure exclusively, subject to Adaptive’s right to terminate the Commercial Agreement for breach or nonperformance as set forth in the Commercial Agreement. Accordingly,
Adaptive will wind down any existing agreements it may have with other cloud service providers within eighteen (18) months after the Effective Date. Notwithstanding anything to the contrary in this paragraph, (a) Adaptive’s obligation
to use Azure exclusively does not apply to applications or services that Adaptive acquires from Third Parties for which the Third Party provider controls selection of the cloud services provider that hosts such application or service (e.g.,
Salesforce or MerrillEdge applications or services) and (b) in the event that Adaptive acquires another entity or the assets thereof, whether by merger, purchase of equity or assets or otherwise, Adaptive shall have a period of eighteen
(18) months following the closing of such acquisition to wind down any existing agreements such other entity may have with other cloud service providers. Further, Adaptive will not, and will not authorize any Third Party to, promote, market or
otherwise publicly discuss Adaptive’s use of any Third Party cloud service provider to host any Adaptive Offering after the Effective Date. 

6.3    Exclusive Use of Immunomics AI Services by Adaptive. Adaptive agrees that throughout the Development Term it
(a) will use the Immunomics AI Services exclusively for TCR-antigen mapping in connection with any Adaptive Offering developed as a direct result of the Collaboration and for which use of services similar
to the Immunomics AI Services is relevant and (b) will not sublicense its rights under Sections 4 and 5 hereof for the purpose of circumventing the foregoing clause (a). The Parties anticipate that the Immunomics AI Services will be relevant
(and therefore Adaptive will use exclusively the Immunomics AI Services pursuant to the previous sentence) in connection with any diagnostic applications for one or a set of medical conditions developed as a direct result of the Collaboration
(“Diagnostic Products”). The Parties anticipate that the Immunomics AI Services may also be relevant to some (but not the preponderance of) therapeutic applications for one or a set of medical conditions developed as a direct result
of the Collaboration (“Therapeutic Products”), and that Adaptive will use the Immunomics AI Services exclusively in all relevant Therapeutic Products cases but that Adaptive will also make available Therapeutic Products that do not
use the Immunomics AI Services or any similar services. Notwithstanding anything to the contrary in this Section 6.3, if Adaptive identifies alternative services that it reasonably determines would provide superior business or technical
performance, as compared to the Immunomics AI Services, in connection with one or more Adaptive Offerings developed as a direct result of the Collaboration and for which such services are relevant, Adaptive may notify Microsoft in writing of the
information and analysis on which Adaptive has based such a determination (an “Alternative AI Service Notice”). If Adaptive delivers an Alternative AI Service Notice to Microsoft, the Parties’ Relationship Managers will
promptly meet to discuss the information and analysis it contains and, if the Parties agree that Microsoft cannot reasonably cause the Immunomics AI Services to provide at least equivalent business and technical performance to the alternative
services identified by Adaptive for the particular use identified in the Alternative AI Service Notice (the “Target Use”), within one hundred twenty (120) days (or such other time period as the Parties may agree is commercially
reasonable), Adaptive may thereafter use alternative services in place of the Immunomics AI Services for the Target Use (as used by applicable Adaptive Offerings) notwithstanding the terms of this Section 6.3. 

  
 Confidential 

7 

 6.4    Exclusive Use of Azure for Diagnostic Products. Adaptive
agrees to host each Diagnostic Product exclusively on Azure throughout the Development Term and the five (5) year period immediately following the Development Term, subject to Adaptive’s right to terminate the Commercial Agreement for
breach or non-performance as set forth in the Commercial Agreement. 

6.5    Microsoft and Adaptive Business Exclusivity Commitments. Microsoft and Adaptive each agree that during the
Development Term, neither such Party nor any of such Party’s Affiliates will enter into any collaboration agreement or other arrangement, with any Third Party under which such Party or any of such Party’s Affiliates agrees to provide
custom services in support of any project that is substantially similar to the Project. For clarity, this paragraph does not limit either Party’s right to enter into, maintain and perform in accordance with Ordinary Course Relationships with
any and all Third Parties, including Third Parties that may be undertaking projects in mapping TCR-antigen associations, provided that each Party will not disclose or provide any of the other Party’s
Confidential Information to any Third Parties except in accordance with the NDA and the terms of Section 7 of this Agreement and provided further that such Ordinary Course Relationships are consistent with each Party’s rights set forth in
Sections 4 and 5 hereof. As used herein, “Ordinary Course Relationships” with respect to Microsoft means Microsoft’s provision of on-premises software, Azure, Office 365 and other cloud
services, and associated updates, upgrades, technical support, general research and consulting services (including in the fields of artificial intelligence and machine learning not substantially similar to the Project). Adaptive acknowledges that
Microsoft has estimated that as of the Effective Date, it provides Offerings under Ordinary Course Relationships to more than 150,000 life sciences and health care entities. As used herein, “Ordinary Course Relationships” with
respect to Adaptive means Adaptive’s ordinary course agreements, licenses, arrangements and relationships with pharmaceutical companies, therapeutics companies, diagnostics companies, clinical laboratory companies, academic and research
institutions and governmental bodies, agencies and institutions that are, in each case, not substantially similar to the Project. 

7.    CONFIDENTIALITY; PUBLICITY AND RELATED ACTIVITIES 

7.1    Application of NDA. Subject to the license rights expressly set forth in this Agreement, any disclosures, information
or documents made or shared between the Parties under this Agreement will be governed by the NDA. The terms of the NDA are incorporated in this Agreement by reference and will apply to all Confidential Information (as defined in the NDA) exchanged
between the Parties in connection with this Agreement. In addition, the terms of, and any discussions or negotiations in connection with, this Agreement are Confidential Information for purposes of the NDA. In the event of any conflict between any
provision of this Agreement and any provision of the NDA, the provision of this Agreement will control. If the NDA is terminated during the Development Term, it will nonetheless continue in effect for the purposes of this Agreement for the remainder
of the Development Term and the survival period set forth in Section 11.5 below. 
 7.2    Data
Privacy & Security. No Protected Health Information (as such term is defined in the Health Insurance Portability and Accountability Act of 1996), other than the Protected Health Information necessary for a Party to carry
out the Collaboration, will be provided by a Party to the other Party under this Agreement. If Adaptive intends to makes any Protected Health Information available to Microsoft for use in the Collaboration, Adaptive will first notify Microsoft of
such intent and provide documentation 

  
 Confidential 

8 

 
of: (i) the source of the data, (ii) any required consents, approvals and authorizations necessary for Microsoft to have access to or use such Protected Health Information in the
Collaboration, and (iii) any security, privacy, use restrictions or other requirements that would apply to Microsoft’s access to or use of such Protected Health Information. Microsoft may elect to accept or not to accept receiving access
to the proposed Protected Health Information following its review of such documentation. For clarity, Adaptive is not required to follow the advance notice process described in this paragraph in order to provide to Microsoft, for use in the
Collaboration, anonymous sequencing data (which data must not include any data that could enable the sequencing data to be linked to Protected Health Information of a donor). Microsoft covenants and agrees that it will not store, process or
otherwise take any action with respect to data under the Collaboration that causes Adaptive to be subject to the data privacy or data security laws of any jurisdiction other than the United States of America, without Adaptive’s prior written
consent. 
 7.3    Approval Required for Publicity Activities. Neither Party will: (a) issue any press release or
make any public statement of any kind about or related to this Agreement or the Collaboration without the express prior written consent of the other Party; or (b) use the other Party’s name or Trademark for any purpose without the other
Party’s written consent. Subject to the foregoing, the Parties intend to collaborate on publicity upon entering into this Agreement, including by cooperating to issue a jointly-approved announcement of the overall strategic intent of this
Agreement that includes CEO-level quotes from each Party, and a statement by Adaptive that Azure is the exclusive cloud service that Adaptive plans to use for its scientific and commercial activities. 

8.    REPRESENTATIONS AND WARRANTIES 

8.1    General. Each Party represents, warrants and covenants to the other Party that: 

(a)    It has all necessary rights, power and authority to enter into and perform under this Agreement in accordance with
its terms; 
 (b)    It has not granted, and will not grant, any rights to any Third Party that would conflict with the
terms of this Agreement; 
 (c)    It has not entered into, and will not enter into, any agreement that would conflict
with the terms of this Agreement; 
 (d)    the individual signing this Agreement on its behalf has authority to bind it
to this Agreement: and 
 (e)    Except as otherwise disclosed by Adaptive to Microsoft in the Disclosure Schedule, as
defined in that certain Series F-1 Preferred Stock Purchase Agreement, of even date herewith, by and between Adaptive, Microsoft and the other parties thereto, it has no knowledge (and has not been notified)
of any allegation (or facts that would support an allegation) of any infringement or misappropriation of any Third Party Non-Patent IP or Patent Rights by any Project Material that it contemplates providing
for use in the Collaboration (either in its standalone form or in the use contemplated under this Agreement). 

8.2    Compliance with Laws. In addition to the representations, warranties and covenants set forth in
Section 8.1, 
 (a)    each Party represents, warrants and covenants to the other Party that it will comply with all
Applicable Laws in connection with its performance under this Agreement; 

  
 Confidential 

9 

 (b)    without limiting the foregoing, Adaptive represents, warrants and
covenants that (i) if it makes any personal data available for use in the Collaboration, including any individually identifiable health information, Adaptive will have obtained all consents, approvals, authorizations, permits and waivers
required by Applicable Laws to make such personal data available for such use, and (ii) Adaptive’s provision and use of personal data under this Agreement will in all cases be in accordance with all Applicable Laws; and 

(c)    without limiting the foregoing, Microsoft covenants and agrees that if Adaptive makes any Protected Health
Information available for use in the Collaboration in accordance with Section 8.2(b), Microsoft will use such Protected Health Information in all cases in accordance with all Applicable Laws. 

8.3    Warranty Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS SECTION 8, EACH PARTY DISCLAIMS ALL
OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 

9.    DEFENSE AND INDEMNIFICATION OF CLAIMS 

9.1    Indemnification. Each Party (the “Indemnifying Party”) will defend, indemnify and hold harmless the
other Party, its Affiliates, and their respective successors, directors, officers, employees and agents (each as the “Indemnified Party”) from and against all Claims to the extent that any such Claim is brought against the
Indemnified Party and arises out of or relates to (a) any breach by the Indemnifying Party of any representation, warranty or covenant set forth in Section 8; or (b) the negligent or willful acts or omissions of the Indemnifying Party
or its agents or contractors resulting in any bodily injury or death to any person or loss, disappearance or damage to tangible or intangible property. 

9.2    Indemnification Procedures. Neither Party will have liability under Section 9.1 to the other Party to the
comparative extent that Claims result from the negligent or willful acts of the other Party. As a condition of its rights under Section 9.1, the Indemnified Party will provide the Indemnifying Party with reasonably prompt notice of an
indemnifiable Claim under this Section 9; permit the Indemnifying Party to solely control the defense and settlement of the Claim; and provide the Indemnifying Party with reasonable information and assistance to help the Indemnifying Party
defend the Claim at the Indemnifying Party’s expense. Any Indemnified Party will have the right to employ separate counsel and participate in the defense of any such Claim at its own expense. 

9.3    Acknowledgment of Fault and Settling Claims. Neither Party will stipulate, admit or acknowledge any fault or
liability on the part of the other without the other’s prior written consent. Neither the Indemnifying Party nor the Indemnified Party (if it has tendered the Claim for indemnity) will settle any indemnifiable Claim under this Section 9 or
publicize any settlement without the other Party’s prior written consent. 
 10.    LIMITATIONS OF LIABILITY 

10.1    Exclusion of Certain Damages. SUBJECT TO SECTION 10.3, NEITHER PARTY WILL BE LIABLE FOR ANY INDIRECT, CONSEQUENTIAL,
INCIDENTAL, PUNITIVE, OR SPECIAL DAMAGES WHATSOEVER (INCLUDING LOSS OF PROFITS) RELATING TO THIS AGREEMENT OR THE COLLABORATION, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

  
 Confidential 

10 

 10.2    Damages Cap. EXCEPT FOR THE EXCLUSIONS IN SECTION 10.3, THE
MAXIMUM, TOTAL, AGGREGATE LIABILITY OF EACH PARTY TO THE OTHER, AND TO ANY THIRD PARTY, FOR ANY AND ALL CLAIMS OR LIABILITIES ARISING UNDER THIS AGREEMENT IS $1,000,000 U.S. DOLLARS OR, IN THE EVENT OF A BREACH OF SECTION 8.2, $5,000,000 U.S.
DOLLARS. 
 10.3    Exclusions. Sections 10.1 and 10.2 do not apply to: 

(a)    any infringement or misappropriation of a Party’s Non-Patent IP or
Patent Rights by the other Party; 
 (b)    any breach by either Party of its obligations set forth in Section 7; or

 (c)    either Party’s obligations under Section 9. 

10.4    Failure of Essential Purpose. If any remedy under this Agreement is determined to have failed of its essential
purpose, all limitations of liability and exclusions of damages will remain in effect to the maximum extent permitted by Applicable Laws. 

11.    TERM AND TERMINATION 

11.1    Term. This Agreement will be effective on the Effective Date and will continue until the seven (7)-year anniversary
of the Effective Date, unless otherwise terminated pursuant to the terms of this Agreement or extended by written mutual agreement of the Parties (such period, the “Development Term”). If, during the period beginning on the date
twelve (12) months before the end of the Development Term and ending on the date six (6) months before the end of the Development Term, either Party notifies the other Party in writing of its desire to extend the Development Period, the
Relationship Managers and Project Managers for each Party shall meet within thirty (30) days following delivery of such written notice and discuss in good faith potential extension of the Development Term. 

11.2    Mutual Termination. The Parties may mutually agree in writing to terminate this Agreement at any time. 

11.3     Termination for Material Breach. In the event that one Party (as the
“Non-Performing Party”) materially breaches or materially fails to perform its obligations under this Agreement, and fails to cure such material breach or fails to perform such obligations
within thirty (30) days after receipt of written notice by the other Party, then the other Party may immediately terminate this Agreement upon written notice to the Non-Performing Party. For the avoidance
of doubt, failure to achieve technical milestones described in the Development Plan will not be deemed a material breach or a material failure to perform obligations, provided that good faith efforts were exercised by the Party accused of such
breach or failure. Microsoft may also terminate this Agreement upon thirty (30) days written notice to Adaptive if Microsoft terminates for cause the letter agreement being entered into by the Parties concurrent with this Agreement that
contains Adaptive’s minimum guaranteed amounts. 
 11.4    Wrap Up. In the event of any termination or expiration
hereunder, the Parties mutually agree in good faith to (i) promptly cooperate in winding down all Collaboration activities and completing all assignment-related activities contemplated by Section 4.3, and (ii) destroy or return to
each other all Confidential Information in one Party’s possession or control that is owned solely by the other Party and not licensed to such one Party with rights that survive termination or expiration of this Agreement, and, if requested in
writing by the other Party, provide a written certificate confirming compliance with this clause (ii) within sixty (60) days of termination or expiration. 

  
 Confidential 

11 

 11.5    Survival. 

(a)    If Adaptive terminates this Agreement under Sections 11.3, (i) the licenses set forth in Sections 5.2 and 5.3 will
remain in effect in accordance with their terms, and (ii) Section 6.5 will remain in effect through the end of the original Development Term (disregarding the termination of such Development Term pursuant to Section 11.3), after which
it will cease to apply. 
 (b)    If Microsoft terminates this Agreement under Sections 11.3, (i) the exclusive license
granted by Microsoft under Section 5.2(a)(i) and (ii) will automatically become non-exclusive (and, for clarity, this license will remain limited to the Field of Use) and the licenses set forth in
Sections 5.2(a)(iii), 5.2(b), 5.2(c) and 5.3 will remain in effect in accordance with their terms; (ii) Adaptive will automatically be deemed to grant to Microsoft the license described in Section 5.4(b), and (iii) Sections 6.2, 6.3
and 6.4 will remain in effect through the end of the original Development Term (disregarding the termination of such Development Term pursuant to Section 11.3), after which they will cease to apply. 

(c)    Upon any other expiration or termination of the Development Term (i.e., where neither Party has terminated this
Agreement under Sections 11.3), the licenses set forth in Sections 5.2 and 5.3 will remain in effect in accordance with their terms. 

(d)    Upon any expiration or termination of the Development Term, the following designated Sections of the Agreement will
also survive, and all other Sections of the Agreement will terminate except as specified in Sections 11.5(a), (b) or (c) (as applicable): Sections 4, 7, 8, 9, 10, 11.4, 11.5, and 12, as well as Exhibit A to the extent applicable to the
foregoing Sections. 
 12.    MISCELLANEOUS 

12.1    No Obligation/Independent Development. Except as expressly set forth in Sections 6.2 through 6.5, and with
respect to exclusive licenses granted under Section 5 (subject to the terms of Sections 5.4 and 11.5), this Agreement is nonexclusive and does not limit either Party’s independent development, marketing, commercialization or other use of
any technologies, services or products, provided that any independent development is carried out without use of any Foreground Non-Patent IP or the other Party’s Project Materials or Confidential
Information. Additionally, subject to Sections 6.2 through 6.5, this Agreement does not restrict either Party from licensing to any Third Party its respective Background Patent Rights and Background Non-Patent
IP without any approval or any compensation to the other Party. Nothing in this Agreement will be deemed to require either Party to engage in any efforts or activities to Commercialize products or services conceived or developed under the
Collaboration. 
 12.2    Assignment. This Agreement may not be assigned or otherwise transferred by either Party,
nor, except as expressly provided herein, may any right or obligation hereunder be assigned or transferred to a Third Party (excluding, for clarity, any assignment or deemed assignment by Adaptive in connection with a Corporate Event) without the
prior written consent of the other Party, which consent will not be unreasonably withheld, delayed, or conditioned. Any assignment without such prior written consent will be null and void and of no legal effect. If such assignment is permitted, the
assignee will be responsible for and perform all obligations and duties of the assignor pursuant to and in accordance with the terms and conditions of this Agreement. 

  
 Confidential 

12 

 12.3    Notices. All notices and requests in connection with this
Agreement are deemed given as of the day they are received either by messenger, delivery service, or in the United States of America mails, postage prepaid, certified or registered, return receipt requested, and will be addressed to the receiving
Party in accordance with the notice information set forth below the signature block of this Agreement. Each Party may change the persons to whom notices will be sent by giving prior notice to the other. 

12.4    Compliance with Laws. Each Party will comply with all Applicable Laws, including privacy and U.S. Export
Administration Regulations, as well as end-user, end-use, and destination restrictions issued by the U.S. and other governments. 

12.5    Relationship of Parties. The Parties are independent contractors. Neither Party has any express or implied right or
authority to assume or create any obligations on behalf of the other Party or to bind the other Party to any contract, agreement or undertaking with any Third Party. Nothing in this Agreement will be construed to create a partnership, joint venture,
employment or agency relationship between the Parties. 
 12.6    Construction. This Agreement has been negotiated by the
Parties and their respective counsel and will be interpreted fairly in accordance with its terms and without any strict construction in favor of or against either Party. If any provision of this Agreement is determined by a court of competent
jurisdiction to be invalid, illegal, or unenforceable, the Parties will deem the provision to be modified to the extent necessary to allow it to be enforced to the extent permitted by law. If it cannot be so modified, the provision will be deleted
from this Agreement, and the remainder of this Agreement will continue to be binding and enforceable according to its terms. Lists of examples following “including”, “e.g.”, “for example”, or the like are interpreted to
include “without limitation,” unless qualified by words such as “only” or “solely.” This Agreement will be interpreted according to its plain meaning without presuming that it should favor either Party. 

12.7    Third Party Beneficiaries. This Agreement is for the benefit of, and will be enforceable by, the Parties
only. It is not intended to confer any right or benefit on any Third Party. 
 12.8     Governing Law; Jurisdiction and
Venue. The laws of the State of Washington govern this Agreement. In the event of any dispute, if federal jurisdiction exists, the Parties consent to exclusive jurisdiction and venue in the federal courts of the Western Washington, and if
not, the Parties consent to exclusive jurisdiction and venue in the courts located in King County, Washington. The provisions of the 1980 U.N. Convention on Contracts for the International Sale of Goods do not apply. Both Parties waive all defenses
of lack of personal jurisdiction and forum non conveniens. Process may be served on either Party in the manner authorized by applicable law or court rule. If either Microsoft or Adaptive employs attorneys to enforce any rights arising out of
or relating to this Agreement, the substantially prevailing Party will be entitled to recover its costs, including reasonable attorneys’ fees. 

12.9    Taxes. Each Party will be responsible for the payment of its own tax liability arising from entry into or
performance under this Agreement or any activities contemplated by it. 
 12.10     Compliance with Laws. Anything
contained in this Agreement to the contrary notwithstanding, the obligations of the Parties hereto will be subject to all laws, present and future, of any government entity having jurisdiction over the Parties hereto, and to orders, regulations,
directions or requests of any such government entity. 

  
 Confidential 

13 

 12.11    Use of Contractors. If a Party uses any Third Party
contractors in performance under this Agreement, such Party will take all necessary steps to have such contractors comply with all terms and conditions of this Agreement, including without limitation confidentiality, and will be responsible for the
breach of this Agreement by any such contractor. Each Party will require that its Third Party contractors assign to it all right, title and interest in any work product, materials, data and intellectual property rights created by such Third Party
contractor in connection with activities under the Collaboration. 
 12.12    Modification; Waiver. This Agreement may be
modified, amended, or altered, or any rights under this Agreement waived, only by a written instrument signed by a duly authorized representative of each Party. The waiver of any breach or default will not constitute a waiver of any other right
under, or any subsequent breach or default of, this Agreement. 
 12.13    Entire Agreement. This Agreement
(together with the NDA and each exhibit attached hereto, each of which is incorporated herein by this reference) constitutes the entire understanding and agreement between the Parties with respect to the subject matter hereof and merges and
supersedes any and all prior or contemporaneous, electronic, oral, or written agreements, understandings, representations, negotiations, discussions, communications, or proposals, whether implied or express. 

12.14    Counterparts; Electronic Signature Process. This Agreement may be executed in two or more counterparts, each
of which will be deemed an original, but all of which together will constitute one and the same instrument. This Agreement may be executed by electronic means. 

[Remainder of page left blank intentionally.] 

  
 Confidential 

14 

 SIGNATURE PAGE 

IN WITNESS WHEREOF, the Parties have executed this Agreement by each of their duly authorized representatives and it will be effective as of the
Effective Date. 
  

									
	ADAPTIVE BIOTECHNOLOGIES CORPORATION	 		 	   MICROSOFT CORPORATION

									
					
	Signature:	 	/s/ Chad M. Robins	 		 	Signature:	 	/s/ Peter K. Lee

									
	Print Name:	 	Chad M. Robins	 		 	Print Name:	 	Peter K Lee

									
	Print Title:	 	 CEO & Co-Founder

Adaptive Biotechnologies
	 		 	Print Title:	 	CVP, Microsoft Research

									
	Signature Date:	 	12/8/17	 		 	Signature Date:	 	December 11, 2017

  

									
	Notice and Contact Information
					
	Address:	 	 1551 Eastlake Ave E
 Seattle, WA 98102
U.S.A.
	 		 	Address: 	 	 One Microsoft Way 
 Redmond, WA 98052
U.S.A.

									
	Business Contact:	 		 		 	Business Contact:	 	

									
	Phone Number:	 		 		 	Phone Number:	 	

									
	Fax Number:	 		 		 	Fax Number:	 	

									
	E-Mail Address:	 		 		 	E-Mail Address:	 	

									
	All legal notices must also be sent to the address above, attention General Counsel, Gene DeFelice.	 		 	      All legal notices must also be sent to the address above, attention

     Deputy General Counsel, Artificial Intelligence & Research Group.

  
 Confidential 

15 

 EXHIBIT A 

Definitions 
 Initially capitalized terms
used in this Agreement will have the meanings set forth in this Exhibit A or as otherwise specified in the Agreement, including its Exhibits. 

“Adaptive’s Outputs” means (a) the Input Data and (b) all Computational Models developed, authored, or otherwise created by
the Parties’ employees, agents, or contractors individually or jointly as part of the Collaboration. 
 “Affiliate” means any legal
entity that Controls, is Controlled by, or is under common Control with a Party or other specified entity. An entity will be deemed an “Affiliate” of the applicable Party or specified entity only so long as such Control exists. 

“Algorithm” means a computational specification and associated software for data processing and calculations that takes Input Data and
generates and executes Computational Models. 
 “Applicable Laws” means all applicable international, federal, state and local laws,
ordinances, regulations, orders and other legal requirements, now or hereafter in effect, of governmental authorities having jurisdiction. 
 “Azure
Services” or “Azure” means one or more of the Microsoft services and features identified at http://azure.microsoft.com/en-us/, and any updates, new versions and successors to such
services or features. 
 “Claim” means any lawsuit, action, proceeding, investigation by any governmental authority, demand, or other claim
by any Third Party, together with any related cash liabilities, damages, costs, and expenses (including attorneys’ fees). 

“Collaboration” means all activities undertaken by the Parties, separately or jointly, pursuant to this Agreement. 

“Commercialize” means to use, copy, reproduce, sell, offer to sell, import, display, distribute, license, translate, publicly display,
publicly perform, create derivative works of, broadcast, transmit, rent, lease, lend and otherwise exploit Non-Patent IP within the scope specified in an applicable provision of this Agreement. Any license
granting the right to Commercialize Non-Patent IP includes the right for the licensee to grant sublicenses to vendors or contractors solely for purposes of the authorized Commercialization. 

“Computational Model” means a mathematical representation, generated by applying Algorithms to Input Data, of various mappings or predictions
of interest related to TCR-antigen associations. 
 “Control” means, as to an entity or person,
owning a majority of the outstanding equity interests of such entity or person or having the right (whether or not contingent) to control the appointment of a majority of the directors or officers of such entity or person or to otherwise manage or
direct the operations of such entity or person. 

  
 Confidential 

16 

 “Corporate Event” shall have the meaning set forth in Adaptive’s Amended and Restated
Articles of Incorporation, as in effect on the date hereof. 
 “Development Plan” means the document attached as Exhibit B that
describes the activities to be carried out as the Collaboration, or such updated or modified version of such document as may be mutually approved by the Parties in accordance with Section 2.1. 

“Field of Use” means diagnostics, therapeutics, or immunological research. 

“Immunomics AI Services” means software and cloud-hosted services that use the Algorithms and Computational Models to implement and execute
applications. For clarity, Immunomics AI Services do not include Algorithms. 
 “Input Data” means TCR, antigen, and binding information,
as well as any associated metadata or clinical data such as patient medical records, in each case as owned, developed or licensed by Adaptive or which Adaptive otherwise has the right to use. 

“Microsoft’s Outputs” means the Immunomics AI Services and all Algorithms developed, authored, or otherwise created by the Parties’
employees, agents, or contractors individually or jointly as part of the Collaboration. 
 “NDA” means the
Non-Disclosure Agreement entered into between the Parties dated July 21, 2017, as set forth in Exhibit D. 

“Non-Patent IP” means all intellectual property rights worldwide, existing under statute or at common
law or equity, in force or recognized now or in the future, with the exceptions of Patent Rights and Trademarks. Non-Patent IP includes, without limitation (except as set forth in the foregoing sentence): (a)
copyrights, trade secrets, and mask works; (b) any application or right to apply for these rights; (c) all renewals, extensions, and restorations of these rights; and (d) any other intellectual property rights in data or research
materials. 
 “Background Non-Patent IP” means all
Non-Patent IP owned or controlled by a Party or its Affiliates that is (i) developed, authored, obtained or acquired before the Effective Date (together with any improvements, modifications or derivatives
of the foregoing developed, authored, obtained or acquired after the Effective Date and arising from the Collaboration), or (ii) developed, authored, obtained or acquired independently from the Collaboration. For clarity, Computational Models
will not be deemed to be derivatives of the Algorithms that generate them. 
 “Foreground Non-Patent
IP” means all Non-Patent IP developed or authored by the Parties’ employees, agents, or contractors individually or jointly as part of the Collaboration, but excluding any Background Non-Patent IP. 
 “Offering,” as to either Party, means any technology, service, product or component of
any of the foregoing, including internal, preview, pre-release and generally available versions; any specification or other proposal for any such technology, service, product or component; and any
documentation for any such technology, service, product or component. 

  
 Confidential 

17 

 “Patent Rights” means all patent rights worldwide, existing under statute or at common law
or equity, in force, or recognized now or in the future, including: (a) patents or applications, inventions, and designs; and (b) any applications, registrations or rights to apply for the foregoing rights, and all renewals, extensions,
continuations, divisionals, re-issues, and restorations. 
 “Background Inventions” means Patent
Rights owned or controlled by a Party or its Affiliates that are (i) developed, conceived, reduced to practice, obtained or acquired before the Effective Date (together with any improvements and modifications of the foregoing developed,
conceived, reduced to practice, obtained or acquired after the Effective Date and arising from the Collaboration), or (ii) developed, conceived, reduced to practice, obtained or acquired independently from the Collaboration. For clarity,
Computational Models will not be deemed to be improvements or modifications of the Algorithms that generate them. 
 “Adaptive Foreground
Inventions” means Patent Rights developed, conceived or reduced to practice solely by Adaptive’s employees, agents, or contractors as part of the Collaboration, but excluding any Background Inventions. 

“Joint Foreground Inventions” means Patent Rights developed, conceived or reduced to practice jointly by one or more of Adaptive’s
employees, agents, or contractors and one or more of Microsoft’s employees, agents, or contractors as part of the Collaboration, but excluding any Background Inventions. 

“Microsoft Foreground Inventions” means Patent Rights developed, conceived or reduced to practice solely by Microsoft’s employees,
agents, or contractors as part of the Collaboration, but excluding any Background Inventions. 
 “Project Materials” means all pre-existing (i.e., not created or developed under the Development Plan) technologies, tools, materials and data that are provided by either Microsoft or Adaptive for use in the Collaboration, excluding any
Background Non-Patent IP and any Background Inventions. 
 “Sell” means to make, have made, use,
sell, offer to sell and import under the applicable Patent Rights within the scope specified in an applicable provision of this Agreement. 
 “Third
Party” means a person or entity that is not an Affiliate of a Party. 
 “Trademark” means any word, phrase, name, trade name,
trademark, logo, brand, trade dress, acronym, symbol, emblem or other identifier that identifies and distinguishes the source of goods or services associated therewith. 

  
 Confidential 

18 

 EXHIBIT B 

Development Plan 
 Collaborative
Development Plan for 
 The Microsoft/Adaptive Biotechnologies TCR-Antigen Map Project 

Vision 
 We aim to translate the scale and precision of the
adaptive immune system to diagnose and treat disease. More specifically, we seek to develop a universal disease diagnostic based on a single blood draw and T-cell Receptor (TCR) sequencing. 

Problem 
 [***] Adaptive has technologies for sequencing TCRs at
scale, and has initial demonstration that the TCR repertoire is predictive of infection with certain pathogens and cancers, as well as predictive of responses to certain antigens. However, the existing predictive models are limited in scope (order
10 antigens, and single infections) and their accuracy is not high enough for clinical use. 
 Solution 

[***] 
 Operational Governance 

Executive Sponsors. Peter Lee (MSFT), Chad Robins (Adaptive) 

Project Managers. Desney Tan and Jonathan Carlson (MSFT), Sean Nolan and Harlan Robins (Adaptive) 

Specific named individuals may change over time as appropriate to support success of the project. 

Roles and Responsibilities. Adaptive will provide Immunology expertise and drive data acquisition; Microsoft will provide Machine Learning
(ML) expertise and drive algorithmic and software development. Data acquisition may include acquisition of samples, TCR sequencing, and related bioinformatic and infrastructure software. Adaptive will grant Microsoft access to existing TCR,
binding and clinical data, and the two teams will work together to develop a data acquisition strategy. Microsoft will provide ML algorithm development and cloud-based services that ingest TCR sequences and output diagnostic and/or antigen binding
predictions. We expect that data acquisition will adapt to the needs of the ML models over time. As appropriate during the course of the project, Adaptive and Microsoft will collaboratively determine milestones, target diseases and use cases, and go-to-market strategies. 
 The Adaptive technical team will initially be made up
of [***] including lab, computational biology and software resources. This project will represent a significant portion of Adaptive’s portfolio; additional laboratory and other resources are envisioned to be committed. 

The Microsoft technical team will comprise a combination of dedicated researchers and engineers spending the majority of their energy on the TCR-Antigen Mapping Project, as well as a larger set of internal collaborators adding specific expertise at appropriate points in the project. The team is expected to [***]. Additionally, Microsoft intends to
mobilize non-technical Microsoft resources, including marketing and communications, business development, privacy and compliance, as well as field and sales teams. 

  
 Confidential 

Certain information, as identified by [***], has been excluded from this agreement because it (i) is not material and (ii) would be competitively harmful
if publicly disclosed. 

 The above is for planning purposes only and subject to ongoing assessment and adjustment as the project
proceeds. 
 Communications and Cadence. Communication will be broadly encouraged at all levels of the project and teams. To facilitate, we
anticipate frequent in-person meetings among the principals, and regular meetings that include the entire team. Teams will (separately or collaboratively) provide status reports at similar cadence. 

At least bi-annually, the Executive Sponsors will, together with appropriate team members, meet to review progress and
discuss outstanding issues or proposed changes in direction or priority. These checkpoints will provide a mechanism to ensure attention to long-term success, but are not intended to delay important decision-making or limit communication between team
members in any way. 
 Project Roadmap and Schedule 
 [***]

 Note that this project requires a significant amount of R&D, and strong emphasis will be placed on pivoting quickly and not being tied to a
preconceived path. This roadmap is thus an example of how we expect this project may proceed. 
 Year 1 

[***] 
 Year 2-3

 [***] 
 Year
4-6 
 [***] 

Year 10 
 [***] 

  
 Confidential 

Certain information, as identified by [***], has been excluded from this agreement because it (i) is not material and (ii) would be competitively harmful
if publicly disclosed. 

 Exhibit C 

Escalation Procedures 
 The Parties will
work together to resolve disputes that may arise under this Agreement in a collaborative fashion. If a dispute arises that the Parties are unable to resolve in their normal course of operations, then, except with respect to issues described in
Section 7 of this Exhibit C, each Party agrees to use the escalation process described in Section 2 through Section 4 of this Exhibit C (“Formal Escalation”) to resolve the dispute (an “Escalated
Dispute”) and each Party agrees to suspend pursuit of any other remedies to which it may be entitled with respect to the Escalated Dispute until completion of Formal Escalation. 

 

	 	1.	 Relationship Managers. As of the Effective Date, each Party has designated the following individual to
serve as its Relationship Manager: 

  

					
	                       	 	Adaptive Relationship Manager:	 	 
			
		 	Microsoft Relationship Manager:	 	 

  

	 	2.	 Notice of Formal Escalation. One Party ‘s Relationship Manager will provide written notice to the
other Party’s Relationship Manager that they wish to invoke Formal Escalation (“Notice of Escalation”). 

  

	 	3.	 First Negotiation Period. During the fifteen (15) calendar days immediately following receipt of
the Notice of Escalation, or such other time period on which the Parties agree in writing (such period, the “First Negotiation Period”), each Party will have its Relationship Manager engage in good faith negotiations (in person or
by phone) with the other Party’s Relationship Manager to resolve the Escalated Dispute. 

  

	 	4.	 Escalation to Supporting Sponsors. If the Escalated Dispute is not resolved by the end of the First
Negotiation Period, then each Party will have a senior executive promptly engage in good faith negotiations with the other Party’s senior executive (in person, unless otherwise agreed in writing by the Parties) during the fifteen
(15) calendar days immediately following the end of the First Negotiation Period, or such other time period on which the Parties agree in writing, to resolve the Escalated Dispute (such period, the “Second Negotiation Period”).

  

	 	5.	 Resolved Disputes. If the Escalated Dispute is resolved at any stage during Formal Escalation then, as
appropriate, the Relationship Managers will oversee implementation of the decision of the Parties resolving the dispute, provided, however, that any amendment, modification or alteration of or any waiver under this Agreement shall comply with the
provisions set forth in Section 12.12 of this Agreement. 

  

	 	6.	 Unresolved Disputes. If the Escalated Dispute is not resolved by the end of the Second Negotiation
Period, then each Party will be entitled to pursue any remedy to which such Party is entitled under this Agreement, at law or in equity. 

  
 Confidential 

	 	7.	 Exclusions from Formal Escalation. Formal Escalation will not apply to or limit the right of a Party:
(i) to seek a temporary restraining order or other provisional remedy to preserve the status quo or to prevent irreparable harm; or (ii) to exercise its termination rights under Section 11 of this Agreement. 

  
 Confidential 

 Exhibit D 

Non-Disclosure Agreement 

Microsoft 
  

Non-Disclosure Agreement 

This Non-Disclosure Agreement (“agreement”) is between the patties signing below. “We,”
“us” and “our” refer to both of the patties signing below and our respective affiliates. 
  

					
	 COMPANY AND ITS AFFILIATES or 

INDIVIDUAL: Adaptive Biotechnologies
	 		 	 MICROSOFT CORPORATION
 AND ITS
AFFILIATES

	Address: 1551 Eastlake Ave E	 		 	 One Microsoft Way
 Redmond, WA
98052-6399

	 Seattle, WA
 98102
	 	
	USA	 		 	USA
			
	Sign: /s/ Gene DeFelice	 		 	/s/ Lucy Bassli
			
	Print Name: GENE DEFELICE	 		 	Lucy Bassli (CELA)
	Print Title: Senior Vice President, General Counsel	 		 	
	Signature Date:7/21/17	 		 	21-Jul-17

 For information about this agreement, contact the Microsoft Contact, Vikram Dendi. 

1.    The purpose of this agreement. This agreement allows us to disclose confidential information to each other, to our own
affiliates and to the other’s affiliates, under the following terms. An “affiliate” is any legal entity that one of us owns, that owns one of us or that is under common control with one of us. “Control” and “own”
mean possessing a 50% or greater interest in an entity or the right to direct the management of the entity. 
 2.    Confidential
information. 
 a.    What is included. “Confidential information” is non-public information, know-how and trade secrets in any form that: 
  

	 	•	 	 Are designated as “confidential”; or 

 

	 	•	 	 A reasonable person knows or reasonably should understand to be confidential. 

b.    What is not included. The following types of information, however marked, are not confidential information.
Information that: 
  

	 	•	 	 Is, or becomes, publicly available without a breach of this agreement; 

 

	 	•	 	 Was lawfully known to the receiver of the information without an obligation to keep it confidential;

  

	 	•	 	 Is received from another source who can disclose it lawfully and without an obligation to keep it confidential;

  

	 	•	 	 Is independently developed; or 

 

	 	•	 	 Is a comment or suggestion one of us volunteers about the other’s business, products or services.

  
 Confidential 

 3.    Treatment of confidential information. 

 

	 	a.	 In general. Subject to the other terms of this agreement, each of us agrees: 

 

	 	•	 	 We will not disclose the other’s confidential information to third parties; and 

 

	 	•	 	 We will use and disclose the other’s confidential information only for purposes of our business relationship
with each other. 

  

	 	b.	 Security precautions. Each of us agrees: 

 

	 	•	 	 To take reasonable steps to protect the other’s confidential information. These steps must be at least as
protective as those we take to protect our own confidential information; 

  

	 	•	 	 To notify the other promptly upon discovery of any unauthorized use or disclosure of confidential information;
and 

  

	 	•	 	 To cooperate with the other to help regain control of the confidential information and prevent further
unauthorized use or disclosure of it. 

  

	 	c.	 Sharing confidential information with affiliates and representatives. 

 

	 	•	 	 A “representative” is an employee, contractor. advisor or consultant of one of us or one of our
respective affiliates. 

  

	 	•	 	 Each of us may disclose the other’s confidential information to our representatives (who may then disclose
that confidential information to other of our representatives) orly if those representatives have a need to know about it for purposes of our business relationship with each other. Before doing so, each of us must: 

 

	 	•	 	 ensure that affiliates and representatives are required to protect the confidential information on terms
consistent with this agreement; and 

  

	 	•	 	 accept responsibility for each representative’s use of confidential information. 

 

	 	•	 	 Neither of us is required to restrict work assignments of representatives who have had access to confidential
information. Neither of us can control the incoming information the other will disclose to us in the course of working together, or what our representatives will remember, even without notes or other aids. We agree that use of information in
representatives’ unaided memories in the development or deployment of our respective products or services does not create liability under this agreement or trade secret law, and we agree to limit what we disclose to the other accordingly.

  

	 	d.	 Disclosing confidential information if required to by law. Each of us may disclose the other’s
confidential information if required to comply with a court order or other government demand that has the force of law. Before doing so, each of us must seek the highest level of protection available and, when possible, give the other enough prior
notice to provide a reasonable chance to seek a protective order. 

 4.     Length of confidential
information obligations. 
  

	 	a.	 Termination. This agreement continues in effect until one of us terminates it. Either of us may
terminate this agreement for any reason by providing the other with 30 days’ advance written notice. Termination of this agreement will not change any of the rights and duties made while this agreement is in effect. 

 

	 	b.	 No other use or disclosure of confidential information. Except as permitted above, neither of us will
use or disclose the other’s confidential information for five years after we receive it. The five-year time period does not apply if applicable law requires a longer period. 

  
 Confidential 

 5.    General rights and obligations. 

 

	 	a.	 Law that applies; jurisdiction and venue. The laws of the State of Washington govern this agreement. If
federal jurisdiction exists, we each consent to exclusive jurisdiction and venue in the federal courts in King County, Washington. If not, we each consent to exclusive jurisdiction and venue in the Superior Court of King County, Washington.

  

	 	b.	 Compliance with law. Each of us will comply with all export laws that apply to confidential information.

  

	 	c.	 Waiver. Any delay or failure of either of us to exercise a right or remedy will not result in a waiver
of that, or any other, right or remedy. 

  

	 	d.	 Money damages insufficient. Each of us acknowledges that money damages may not be sufficient
compensation for a breach of this agreement. Each of us agrees that the other may seek court orders to stop confidential information from becoming public in breach of this agreement. 

 

	 	e.	 Attorneys’ fees. In any dispute relating to this agreement the prevailing party will be entitled to
recover reasonable attorneys’ fees and costs. 

  

	 	f.	 Transfers of this agreement. If one of us transfers this agreement, we will not disclose the
other’s confidential information to the transferee without the other’s consent. 

  

	 	g.	 Enforceability. If any provision of this agreement is unenforceable, the parties (or, if we cannot
agree, a court) will revise it so that it can be enforced. Even if no revision is possible, the rest of this agreement will remain in place. 

  

	 	h.	 Entire agreement. This agreement does not grant any implied intellectual property licenses to
confidential information, except as stated above. We may have contracts with each other covering other specific aspects of our relationship (“other contracts”). The other contract may include commitments about confidential information,
either within it or by referencing another non-disclosure agreement. If so, those obligations remain in place for purposes of that other contract. With this exception, this is the entire agreement between us
regarding confidential information. It replaces all other agreements and understandings regarding confidential information. We can only change this agreement with a signed document that states that it is changing this agreement.

  
 ConfidentialEX-10.4

 Exhibit 10.4 

Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly
disclosed. 
 MASTER COLLABORATION AGREEMENT 

This Master Collaboration Agreement (this “Agreement”) is made effective as of July 10, 2015 by and between ADAPTIVE
BIOTECHNOLOGIES CORPORATION, a Washington corporation (“Adaptive”), and Adaptimmune Limited, a limited company formed under the laws of England and Wales (“Collaborator” and together with Adaptive, the
“Parties”). 
 BACKGROUND 

Collaborator desires to access Adaptive’s advanced immune profiling technology to facilitate its business of developing and commercializing
pharmaceutical products. The Parties have therefore entered into this Agreement to set forth the terms and conditions of their research collaboration. 

AGREEMENT 
 1. SCOPE OF COLLABORATION

 (a)    Projects. Adaptive hereby agrees to collaborate with Collaborator on such projects as may be
mutually agreed to by the Parties in writing from time to time (each, a “Project”). This Agreement sets forth the general terms and conditions applicable to the work to be performed with respect to any and all Projects. 

(b)    Project Orders. With respect to each Project, Adaptive and Collaborator will prepare and execute a written
project order (each a “Project Order”) setting forth the specific tasks to be performed by each Party, the timeline for performing the tasks, the estimated fees and expenses associated with the tasks, the payment schedule applicable
to the tasks, format of deliverables associated with the tasks, and any other matters deemed appropriate by Adaptive and Collaborator. Either Party may accept or reject a proposed Project Order for any reason in its sole discretion, and no Project
Order will be effective until executed by both Parties. As appropriate, Project Orders will logically and/or sequentially order and/or group tasks and note decision points. Each mutually executed Project Order will be attached to this Agreement.

 (c)    Conflicts. In the case of a conflict between the terms of this Agreement and a Project Order, the terms
and conditions of this Agreement will control unless Adaptive and Collaborator specifically acknowledge in the Project Order their intent to modify the terms and conditions of this Agreement. 

2. OBLIGATIONS OF COLLABORATOR 

(a)    Provision of Collaborator Materials. Collaborator will supply all biological samples and any related
information reasonably required to carry out the Projects conducted under this Agreement and which Collaborator has in its possession and control, including those described in the applicable Project Order (collectively, the
“Materials”) in such formats as Adaptive may reasonably request or as otherwise set forth in more detail in a Project Order. All Materials will be deemed Confidential Information of Collaborator within the meaning of Section 4.

 (b)    Handling of Materials; De-identification. Collaborator
represents and warrants that (i) as at the time any Material is supplied to Adaptive by Collaborator, Collaborator has the right to send the Materials to Adaptive for all uses contemplated by this Agreement in relation to such Materials, (ii)
the 

 
Materials contain no information that could be used to identify the individuals from which such Materials were derived, and (iii) proper informed consent has been obtained for the transfer
of the biological samples and other Materials to Adaptive for the purposes of performing research, including documented approvals of patients or institutional review board that may be required by applicable law or regulation. Collaborator will
notify Adaptive if it becomes aware at any time that it ceases to have the right to supply any Material to Adaptive for the uses contemplated by this Agreement. Adaptive may upload, use, display and modify the Materials and Collaborator Developments
into the immunoSEQTM Analyzer database for storage and use solely for the purposes contemplated under the relevant Project Order. 

(c)    For Research Use Only; Not for Diagnostic Use. In no event will Collaborator use the Collaborator
Developments or other data and results provided by Adaptive hereunder for diagnosing, evaluating or treating individual patients from which the samples were derived. 

3. OBLIGATIONS OF ADAPTIVE 

(a)    Adaptive Obligations Generally. Adaptive will provide the facilities, personnel and other resources required
for the Projects other than biological materials and related information to be supplied by Collaborator. Adaptive will not sub-contract performance of the Projects to any third party without
Collaborator’s prior written consent, other than Adaptive’s wholly owned subsidiary, Sequenta LLC and provided Sequenta LLC is identified in any Project Order as carrying any part of the relevant Project. Adaptive will conduct each Project
with reasonable skill and care, in a good scientific manner, in accordance with the applicable Project Order and in accordance with relevant industry standards and any laws and regulations generally applicable to research laboratories in
Adaptive’s line of business and jurisdiction and to the services being provided by Adaptive. With respect to each Project, Adaptive will communicate regularly with Collaborator and respond to reasonable requests for status updates. Project
Orders will be performed in accordance with the policies set out in Exhibit A to this Agreement. Adaptive will ensure that in performing the Project it uses personnel which are suitably qualified and experienced to perform the activities delegated
to them. 
 (b)    Delivery of Results. Subject to timely receipt of the Materials and payment of amounts due
hereunder, Adaptive will use its commercially reasonable efforts to complete each Project within the timeline established for such Project. Adaptive will keep Collaborator reasonably informed of the progress of the Project as against timelines.
Adaptive will provide the results of each Project to Collaborator in its customary *.TSV format through the immunoSEQ Analyzer software platform (including the entire raw processed data set). Subject to Collaborator’s timely payments of all
amounts accrued hereunder, Adaptive will use its commercially reasonable efforts to retain all Project results for at least 24 months following the completion of each Project. Adaptive will notify Collaborator where reasonably possible prior to any
destruction of any Project results prior the expiration of such period and provide Collaborator with an opportunity to store Project results itself or at a nominated third party. 

(c)    Handling of Biological Materials. Adaptive will test, handle and store all materials supplied by Collaborator
in accordance with Adaptive’s customary handling procedures and any special handling instructions set forth in a Project Order, and will return or destroy all unused biological materials supplied by Collaborator. Samples received by Adaptive
will be handled in accordance with Adaptive SOPs. All arriving packages will be opened the same day they arrive and Inspected thoroughly for correct labeling and packaging integrity. Adaptive will contact Collaborator via phone or email promptly
about any sample receipt issues, including identification, modification in shipping conditions, or condition of the sample which may delay sample processing. Should any sample be deemed unacceptable for processing. Adaptive

  
 2 

 
will communicate with Collaborator about the nature of the issue. More specific handling requirements may be set forth in the Project Order. Materials provided by the Collaborator (and any
derivatives, modifications or progeny of such materials) shall only be used for the performance of the relevant Project Order and must not be provided to any third party. Materials provided by Collaborator (and any derivatives, modifications or
progeny of such materials) and information associated with such materials will constitute Confidential Information of Collaborator. 

(d)    No Debarred Personnel. Adaptive represents that, to its knowledge, no person who will perform activities
under this Agreement has been suspended, debarred or subject to temporary denial of approval, nor is under consideration to be suspended, debarred or subject to temporary denial of approval, by the U.S. Food and Drug Administration from working in
or providing services, directly or indirectly, to any applicant for approval of a drug product or any pharmaceutical or biotechnology company under the Generic Drug Enforcement Act of 1992, as amended. 

(e)    Limited Warranty. Collaborator understands that the Projects are experimental and Adaptive cannot guarantee
any outcome. Collaborator’s sole warranty with respect to the services performed under this Agreement is that Adaptive will perform such services in accordance with generally prevailing industry standards and all laws, rules and regulations
applicable to Adaptive. 
 4. CONFIDENTIALITY 

(a)    Definitions. For purposes of this Agreement, the term “Confidential Information” means any
scientific, technical, trade or business information possessed by a Party which is treated by such Party as confidential or proprietary, including information pertaining to cells, antibodies, organisms, chemical compounds, products, formulations,
technologies, techniques, methodologies, algorithms, computer programs, computer security systems and processes, assay systems, procedures, tests, data, documentation, reports, sources of supply, know-how,
patent positioning, relationships with employees and consultants, business plans, business developments, research, development, process development, manufacturing, commercialization, and marketing, and any other confidential information about or
belonging to a Party’s affiliates, suppliers, licensors, licensees, partners, collaborators, customers or others, and is provided by one Party or its affiliated companies (the “Discloser”) to the other Party (the
“Recipient”) under this Agreement. Without limiting the generality of the foregoing, the Collaborator Materials and the Collaborator Developments (as defined in Section 5) constitute Confidential Information of Collaborator,
and the pricing offered to Collaborator and the other general terms of this Agreement constitute Confidential Information of Adaptive. For the purpose of clarity, the identity of any of Collaborator’s programs or drug development candidates
will be considered Collaborator’s Confidential Information. 
 (b)    Confidentiality Obligation. Each Party
agrees that, except in connection with the performance of its obligations under this Agreement or the exercise of its rights or licenses under this Agreement, it will not otherwise use in any way for its own account or the account of any third
party, nor disclose to any third party, any Confidential Information revealed to it by the other Party; provided, however, that Confidential Information may be disclosed pursuant to a regulation, law, court order or rule of any applicable securities
exchange, but only to the minimum extent required to comply with such regulation, order, or rule and with advance written notice to the Discloser; and provided further that a Recipient may disclose Confidential Information to its subsidiaries,
affiliates, professional advisors, consultants, agents to the extent such entities or individuals require access to the Confidential Information for the performance of obligations under this Agreement or the exercise of rights or licenses

  
 3 

 
under this Agreement provided that they are under confidentiality and use limitations consistent with those in this agreement and such Party will be liable for breaches of the restrictions set
forth in this Section 4 by all such persons. Each Party will take commercially reasonable efforts to protect the confidentiality of the other Party’s Confidential Information, such precaution not to be less than the precautions each Party
takes to protect the confidentiality of its own Confidential Information of the same kind. Collaborator may also disclose Confidential Information of Adaptive to its third-party collaborators where such disclosure is necessary for the performance of
the relevant collaboration that relates to the therapeutic agent that is the subject of the Project or the data and results provided by Adaptive hereunder, provided that they are under confidentiality and use limitations consistent with those in
this agreement and Collaborator will be liable for breaches of the restrictions set forth in this Section 4 by all such persons. Each party will ensure that any Confidential Information of the other Party (including, with respect to
Collaborator, the Collaborator Developments) will be stored securely and can be easily retrieved. 

(c)    Exclusions. For purposes of this Agreement, the term Confidential Information does not include any
information which (i) was known to Recipient at the time it was disclosed, other than by previous disclosure by Discloser; (ii) becomes known by disclosure from a third party without an obligation of confidentiality; (iii) is or
becomes publicly known without breach of this Agreement; or (iv) is independently developed by the Recipient without the use of the Discloser’s Confidential Information. The obligations of confidentiality under this Section 4 will
survive and continue after any expiration or termination of the Project Order under which such Confidential Information was disclosed or this Agreement. 

5. DEVELOPMENTS 

(a)    Ownership of Pre-existing Materials. All information and materials
furnished by a Party pursuant to this Agreement and all associated intellectual property rights will remain the exclusive property of the furnishing Party, including without limitation Collaborator’s ownership of the Materials. All preexisting
or separately developed technology and associated intellectual property rights used by Adaptive in conducting the Projects, including Adaptive’s predictive algorithms, assays and associated methods (collectively the “Adaptive
Technology”), will remain the exclusive property of Adaptive. No rights are granted by either Party to their pre-existing intellectual property except the limited licenses expressly set forth herein.
Collaborator will not attempt to reverse engineer, characterize, or ascertain the chemical structure of Adaptive’s assays or proprietary algorithms or other elements of the Adaptive Technology. 

(b)    Ownership of Project Deliverables. Other than the Adaptive Developments, all results arising from the
performance of a Project (including all associated intellectual property rights in and to such results) will be solely owned by Collaborator (the “Collaborator Developments”). Adaptive hereby assigns and agrees to assign to
Collaborator all of its right, title and interest in and to the Collaborator Developments. Adaptive will solely own the Adaptive Developments and all associated intellectual property rights. The term “Adaptive Developments” means
inventions and discoveries arising from a Project that consist of modifications, refinements or improvements to the Adaptive Technology and all diagnostic applications, provided that in each case the practice of such inventions and discoveries does
not require the use of any pre-existing Confidential Information or intellectual property rights of Collaborator. 

  
 4 

 (c)    The test results, receptor sequences and other data and analysis
will be delivered in the formats specified in the Project Order (or if blank, in a mutually agreed format readily readable by commercially available off-the-shelf
software such as Microsoft Office). Adaptive confirms and represents that the test results, receptor sequences and other data and analysis delivered to Collaborator can be used within any need to access the Adaptive Technology or Adaptive
Developments. 
 (d)    Each party agrees that it shall have sufficient agreements in place with its employees or other
individuals performing the Project to ensure that any intellectual property rights are owned in accordance with this Section 5 and in particular that all Collaborator Developments are owned by Collaborator. Adaptive will provide all reasonable
assistance as may be required to ensure that title to Collaborator Developments vests in Collaborator including as relevant the obtaining of confirmatory assignment agreements from individuals if required in relation to any registration or
prosecution of any intellectual property rights. 
 6. PAYMENTS 

(a)    Sequencing Price; Discounts. ImmunoSEQTM sequencing
pricing is based on the resolution required for the samples in the Project and will be specified in the relevant Project Order. As of the date of this Agreement, the list price per sample for each locus are as follows: $[***] per Survey sample,
$[***] per Deep sample, and $[***] per Ultra Deep sample. [***] 
 (b)    Technology Access Fee. A technology
access fee equal to [***] may be invoiced upon completion of sequencing for each Project for basic bioinformatics and experimental design support, use of immunoSEQ Analyzer 2.0 for [***] months following sequencing of hereunder, and up to [***]
hours of data analysis support. Where applicable such Technology Access Fee will be specified in the Project Order. 

(c)    Professional Services. The technology access fee described above includes basic bioinformatics and
experimental design support. For Projects that require significantly deeper engagement by Adaptive personnel, Adaptive will separately invoice monthly for such professional services at rates and for times mutually agreed by the parties. 

(d)    Project Payment Schedule. The payment schedule for each Project shall be specified in the relevant Project
Order, provided, however, that if no payment schedule is specified Projects with total charges under $[***] will be invoiced [***]% in advance, and for larger Projects Collaborator will pay to Adaptive the assay charges for each Project according to
the payment schedule below: 
  

					
	 First payment [***]
	  	 	[***]%	 
	 Second payment [***]
	  	 	[***]%	 
	 Third payment [***]
	  	 	[***]%	 
	 Completion of the Project
	  	 	[***]%	 

 In this context Completion of the Project constitutes delivery of all deliverables including the final report
in agreed format. 
 All other Project-related charges (including the technology access fee, any applicable taxes, shipping and handling and
professional services fees) and in each case as specified in Project Order or otherwise agreed in writing by Collaborator will be invoiced as accrued. All payments are non-refundable. 

  
 5 

Certain information, as identified by [***], has been excluded from this agreement because it (i) is not material and (ii) would be competitively harmful
if publicly disclosed. 

 (e)    Invoicing; Payments. Adaptive will invoice Collaborator
for each Project in accordance with the payment schedule set forth in the applicable Project Order. Invoiced payments are due within 30 days of receipt. Invoices should be sent to Collaborator at its address stated on the signature page hereto,
Attn: Accounts Payable. For any amounts due under this Agreement that are not paid within [***] days of receipt of invoice, Adaptive may accrue interest at [***]% per month, not to exceed the maximum permitted by applicable law. Adaptive will
provide written notification of non-payment to Collaborator prior to charging any interest or taking any action to recover any overdue amounts. All sums payable under this Agreement will be exclusive of value
added tax or any equivalent sales tax applicable which shall be payable in addition by Collaborator. 
 7. TERM AND TERMINATION 

(a)    Term of Agreement. This Agreement will commence on the date first set forth above and will expire 48 months
thereafter, provided, however, that if one or more Projects remain outstanding and active at the end of such period, the expiration date shall be automatically extended until the scheduled completion date of the last such Project. This
Agreement may thereafter be renewed with the express mutual written consent of the Parties. 
 (b)    Termination.
Either Party may terminate or suspend its performance under this Agreement or a particular Project in the event of a breach of a material term of this Agreement by the other Party, which breach is not cured within [***] business days ([***] business
days in the event of a payment default) after written notice by the non-breaching Party to the breaching Party. 

(c)    Effect of Termination. Termination of this Agreement will simultaneously terminate all Project Orders then
outstanding as of the effective date of termination. In the event of termination, Collaborator will pay all fees and expenses accrued through the effective date of termination. Other than with respect to uncured material breaches by Adaptive, no
refunds will be due upon termination. The provisions of Sections 3(e), 2(b), 4, 5, 6(e), 7(c), 8 and the last two sentences of Section 3(b) will survive termination or expiration of this Agreement for any reason. 

8. MISCELLANEOUS 

(a)    Construction. When a reference is made in this Agreement to a Section, such reference is to a section of this
Agreement unless otherwise indicated. The words “herein,” “hereunder” and “hereof” refer to this Agreement (taken as a whole and together with any relevant Project Orders) and not to any particular provision of this
Agreement. The words “include,” “includes” and “including” will be deemed to be followed by the words “without limitation.” The headings contained in this Agreement are for reference purposes only and will not
affect in any way the meaning or interpretation of this Agreement. The words “agrees to”, “will” and “shall” are used in a mandatory, not a permissive, sense. . All payments hereunder will be made in U.S. dollars. The
Parties specifically disclaim the application of the UN Convention on Contracts for the International Sale of Goods. This Agreement has been written in the English language, and the Parties agree that the English version will govern. 

(b)    Independent Contractors. Adaptive and Collaborator are independent contractors and nothing in this Agreement
will be construed to create a partnership, joint venture, license or employment relationship between the Parties. 

(c)    No Implied Warranties; Limited Remedy. Except as expressly stated elsewhere in this Agreement, NEITHER PARTY
MAKES ANY GUARANTEE OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING 

  
 6 

Certain information, as identified by [***], has been excluded from this agreement because it (i) is not material and (ii) would be competitively harmful
if publicly disclosed. 

 
WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE. THE SOLE REMEDY OF COLLABORATOR FOR BREACH OF
WARRANTY HEREUNDER WILL BE TO REQUIRE ADAPTIVE, AT ADAPTIVE’S ELECTION, TO EITHER RE-PERFORM THE PORTION OF THE PROJECT GIVING RISETO SUCH BREACH AT ADAPTIVE’S COST OR REFUND THE FEES PAID BY
COLLABORATOR FOR THE PORTION OF THE PROJECT THAT GAVE RISETO SUCH BREACH. 
 (d)    LIMITATION OF LIABILITY
GENERALLY. NEITHER PARTY WILL BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES {INCLUDING CLAIMS ARISING FROM LOST DATA AND INDIRECT AND DIRECT LOST PROFITS) (COLLECTIVELY, “LOSSES”), ARISING
OUT OF OR IN CONNECTION WITH THIS AGREEMENT, HOWEVER CAUSED, AND UNDER WHATEVER CAUSE OF ACTION OR THEORY OF LIABILITY BROUGHT (INCLUDING, WITHOUT LIMITATION, UNDER ANY CONTRACT, NEGLIGENCE OR OTHER TORT THEORY OF LIABILITY) EVEN IF SUCH PARTY HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR SUCH DAMAGES WERE OTHERWISE FORESEEABLE. TOTAL CUMULATIVE LIABILITY OF A PARTY IN CONNECTION WITH THIS AGREEMENT AND THE PROJECTS, WHETHER IN CONTRACT OR TORT OR OTHERWISE, WILL NOT EXCEED AN AMOUNT
EQUIVALENT TO THE AMOUNT OF FEES PAID TO ADAPTIVE BY COLLABORATOR UNDER THIS AGREEMENT OVER THE 12-MONTH PERIOD PRECEDING THE EVENT GIVING RISE TO SUCH CLAIM. THE LIMITATION OF LIABILITY UNDER THIS PARAGRAPH
INCLUDING THE EXCLUSION OF LOSSES DOES NOT APPLY TO THE PAYMENT OF FEES AND EXPENSES OWING UNDER THIS AGREEMENT, LOSSES ARISING FROM THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF A PARTY, OR CLAIMS ARISING UNDER SECTION 2, SECTION 4 AND SECTION 5,
OR LOSSES ARISING FROM ANY FRAUD OR FRAUDULENT MISREPRESENTATION. 
 (e)    Notices. All notices under this
Agreement must be in writing and at the applicable address set forth on the signature page to this Agreement or at such other address as a Party may specify in writing. Notices are effective as follows: (i) 3 business days following delivery in the
mail using recorded delivery, (ii) upon delivery if sent via a nationally recognized commercial courier, (iii) upon delivery if hand-delivered, or (iv) sent by email or facsimile, upon
non-automated confirmation of receipt. 
 (f)    Publicity. Any publicity
using the other Party’s name and logo including on a website, in marketing materials or in any press release must be prior approved by the other Party. 

(g)    Publications. Without limiting the generality of Section 4 (“Confidentiality”), each
Party agrees to use reasonable efforts to provide the other Party with advance copies of any publications containing experimental results that directly or Indirectly result from a Project. Such prior provision shall not apply where there are any
third party confidentiality restrictions or such release would breach any applicable laws or regulations affecting the publishing party. In any such publication, the publishing Party will acknowledge the other Party’s contribution (including
authorship if appropriate under the circumstances and customary industry practice). 
 (h)    No Assignment. The
rights and obligations under this Agreement may not be assigned or transferred by either Party without the prior written consent of the other Party, except that either Party may assign this Agreement without such consent to an affiliated company or
in connection with the merger, consolidation, sale or transfer of all or substantially all of a Party’s business to which this Agreement relates. 

(i)    Entire Agreement. This Agreement, taken together with each mutually executed Project Order, constitutes the
entire agreement of the Parties with regard to its subject matter and supersedes all previous oral or written representations, agreements and understandings between Adaptive and Collaborator. Use of the immunoSEQ Analyzer is subject to separate
license terms users must accept as part of the account creation or log-in process. Nothing in this clause shall exclude any liability for fraud or fraudulent misrepresentation. 

  
 7 

 (j)    Amendments; No Implied Waivers. This Agreement may only be
modified in writing, executed by duly constituted officers of both Parties. Any terms and conditions on a purchase order or a bill of lading that conflict with or are in addition to any of the terms of this Agreement will be null and void and
without legal effect unless expressly agreed upon by the Parties in a written document specifically referencing this Section 8(j). Either Party’s waiver of any term or condition of this Agreement at any time will not be construed to waive
such term or condition at subsequent times or any other term or condition, nor as a waiver of its rights to enforce such term or condition. 

(k)    Severability. In the event that any one or more provisions of this Agreement are, for any reason, held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provision of this Agreement, and all other provisions will remain in full force and effect. If any of the provisions are held
to be excessively broad, any such provision will be reformed and construed by limiting and reducing it so as to be enforceable to the maximum extent permitted by law. 

(l)    Governing Law. This Agreement will in all events and for all purposes be governed by and construed in
accordance with the law of New York, without regard to any choice of law principle that would dictate the application of the law of another jurisdiction. The Parties consent to the exclusive jurisdiction of the state and federal courts located in
New York County, New York for all claims or disputes arising in connection with this Agreement. In any suit or action brought to enforce this Agreement, or to obtain an adjudication, declaratory or otherwise, of rights hereunder, the losing Party
will pay to the prevailing Party reasonable attorneys’ fees and all other costs and expenses that may be incurred by the prevailing Party in such suit or action. 

(m)    Counterparts. This Agreement may be executed in counterparts and delivered via facsimile, emailed PDF or
other electronic means, each of which will be deemed to be an original, and both of which taken together, will constitute one agreement binding on both Parties. 

[Signature Page Follows] 

  
 8 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be signed and executed by
their duly authorized officers as of the date first written above. 
  

									
	ADAPTIVE	 		 	COLLABORATOR
					
	By:	 	/s/ Chad M. Robins	 		 	By:	 	/s/ H.K. Tayton-Martin

									
					
	Print Name:	 	Chad M. Robins	 		 	Print Name:	 	H.K. Tayton-Martin

									
					
	Title:	 	CEO, President & Founder	 		 	Title:	 	Chief Operating Officer

									
					
	Address:	 	1551 Eastlake Ave. E., Ste. 200	 		 	Address:	 	91 Park Drive Milton Park
					
		 	Seattle, Washington 98102	 		 		 	Abingdon, England, UK

									
					
	Facsimile:	 	(206) 659-0667	 		 	Facsimile:	 	N/A

									
					
	Email:	 	support@adaptiveblotechnoloeles.com	 		 	Email:	 	N/A

  
 9 

 TEMPLATE FOR PROJECT ORDER NO. 1 

PURSUANT TO MASTER COLLABORATION AGREEMENT 

This Project Order No. 1 (this “Project Order”) is made effective as of
                    , 201     by and between ADAPTIVE BIOTECHNOLOGIES CORPORATION, a Washington corporation
(“Adaptive”), and Adaptimmune Limited,, a limited formed under the laws of England and Wales (“Collaborator”) pursuant to the Master Collaboration Agreement between the Parties dated July 10, 2015 (the
“Agreement”). The activities described in this Project Order will be governed by the terms and conditions of the Agreement. Capitalized terms used herein and not otherwise defined will have the meanings given such terms in the
Agreement. 
 1. PROJECT DESCRIPTION 

(a)    Project Overview and Objectives. 

Exploratory analyses of [INSERT T OR B] cell diversity by [INSERT SEQUENCING DEPTH] sequencing of [INSERT LOCUS TO BE SEQUENCED] will be
performed on [INSERT MATERIAL TYPE] samples. [INSERT MATERIAL TYPE] obtained from Protocol INSERT PROTOCOL NUMBER will be assessed. The sequencing data generated by Adaptive will be used by Collaborator to monitor [INSERT WHAT WE WILL MONITOR]. 

Objectives of the correlative study may include: 
  

	 	•	 	 Determine if a minimum threshold of baseline T cell or B cell diversity correlates with clinical activity

  

	 	•	 	 Characterize the apparent presence/absence and relative quantity of T cell clones during treatment

  

	 	•	 	 Monitor individual sequence frequencies for each patient over the course of therapy and correlate data to
outcomes 

 (b)    Samples. 

Collaborator will provide to Adaptive [INSERT MATERIAL AND NUMBER OF SAMPLES] samples for use in performing the activities described in this
Project Order, together with any related information on a sample manifest as may be reasonably requested by Adaptive to carry out the Project. 

Total of ____ patients: ____ Patients each with ______ time points as follows: 

(c)    Workflow. 

(i)    [INSERT MATERIAL TYPE] samples will be shipped to Adaptive in provided shipping materials. 

(ii)    Samples received by Adaptive will be handled in accordance with Adaptive SOPs. All arriving packages will be opened
the same day they arrive and inspected thoroughly for correct labeling and packaging integrity. Adaptive will contact Collaborator via phone or email promptly about any sample receipt issues, such as but not limited to identification, modification
in shipping conditions, or condition of the sample which may delay sample processing. Should any sample be deemed unacceptable for processing, Adaptive will communicate with Collaborator about the nature of the issue. 

  
 10 

 (iii)    Adaptive will perform “[INSERT SEQUENCING
RESOLUTION)” sequencing on each of the [INSERT SAMPLE SOURCE] samples provided by Collaborator. As part of these analyses, Adaptive uses a proprietary assay for the amplification and massively parallel sequencing of millions of CDR3 regions in
the (INSERT LOCUS TO BE SEQUENCED] using a multiplex PCR amplification across the VDJ junction of rearranged [INSERT LOCUS TO BE SEQUENCED]. 

(d)    Adaptive Deliverables. Within 6-8 weeks of Adaptive’s receipt of
the samples, all raw processed sequence data from the assay of the Materials will made available to Collaborator in *.TSV format through the immunoSEQ Analyzer software platform for download and/or analysis. Subject to timely payment of the
technology access fee, Adaptive will also provide basic level support for Collaborator’s analysis of the samples provided (must be utilized within 30 days of notification of Project data availability; up to 5 hours of Adaptive personnel time)
as set forth below. Adaptive may offer additional professional and analytical services for an additional fee. 
 Sequencing analysis may
include: 
  

	 	•	 	 Identification and quantification of all clones in a given sample, including number of unique clones and
frequency of each clone. 

  

	 	•	 	 Identification and comparison of common clones in all samples (between patients, and between pre-treatment and post-treatment samples for the same patient). 

  

	 	•	 	 Computation of V, D, and J usage in each sample. 

 

	 	•	 	 Comparisons of expansion of clones. 

 

	 	•	 	 Computation of the diversity and clonality of all samples. 

(e)    Results Sharing. Should Collaborator choose to share de-identified
clinical data, Adaptive’s bioinformatics team will also prepare analyses correlating clinical outcomes with sequencing data. 

(f)    Project Schedule. The parties anticipate that the activities contemplated by this Project Order will be
completed over months, with the first samples expected to be shipped to Adaptive in_______ , 201    , and all sequencing completed and results delivered by ____, 201    . 

2. PAYMENTS; INVOICING 

(a)    Invoicing. Adaptive will invoice Collaborator at the address set forth in the Agreement unless an alternate
invoicing address is set forth below. All invoices will reference the applicable Collaborator purchase order number, if any. 
 Optional:
alternate address for invoicing: 
 (b)    Pricing. Services under this Project Order will be billed in accordance
with the pricing set forth in the Agreement. The Parties agree that such compensation reflects the fair market value of the services rendered hereunder. Except for the payments by Collaborator as set forth below, each Party will be responsible for
all costs and expenses it incurs related to the performance of this Project. 
 (c)    Estimated Charges. The
following table sets forth the estimated charges for the Project: 
 [INSERT TABLE] 

  
 11 

 (d)    Estimated Payment Schedule: The following table sets forth
the estimated payment schedule for the Project: 
 [***] [or] [***] 

3. LONG-TERM ARCHIVING 
  

	 	☐	 If this box is checked, the Materials and Collaborator Developments relating to this Project may be released to
the public immunoSEQ data set along with the sequencing results (without attribution to Collaborator) upon the expiration of the confidentiality period described in Section 4 

  
 12 

Certain information, as identified by [***], has been excluded from this agreement because it (i) is not material and (ii) would be competitively harmful
if publicly disclosed. 

 Exhibit A - R&D POLICY PRINCIPLES 

A. Ethical Conduct Requirements Ethical Conduct 

Ethical Conduct 
 The Parties are committed to the highest
standards of conduct in all aspects of their respective businesses and to conduct their business with honesty and integrity, and in compliance with all applicable legal and regulatory requirements. 

 

	 	•	 	 Always act with integrity and honesty and protect the Parties’ public image and reputation in relationships
with customers, competitors, suppliers, business partners and staff 

  

	 	•	 	 Promptly raise any concerns about possible unethical or illegal conduct 

 

	 	•	 	 Be free from actual or potential conflicts of interest that might influence, or appear to influence their
judgment or actions when performing duties on behalf of the Parties 

  

	 	•	 	 The Parties’ reputation and the respect of those who deal with the Parties must not be put at risk by
acceptance of any entertainment, gifts or favours intended or perceived by others to influence their business judgment 

  

	 	•	 	 Communications with external audiences, i.e., investors and the media, should be managed through appointed
company spokespersons to minimize risk to the Parties’ reputation 

  

	 	•	 	 Provide accurate and reliable information in records submitted, safeguard the Company’s confidential
information, and respect the confidential information of other parties with whom the Company does business or competes 

  

	 	•	 	 Comply with all applicable anti-bribery practices legal requirements including U.S. Foreign Corrupt Practices Act
(“FCPA”) and the United Kingdom Bribery Act 2010. In particular no employee of either party shall give or authorize directly or indirectly any illegal payments to government officials of any country. 

 

	 	•	 	 Each employee of a Party should endeavour to deal fairly with the Company’s customers, suppliers,
competitors and employees. No-one should take unfair advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts, or any other unfair-dealing
practice. 

 B. Requirements for Engaging External Experts  

Use of External Experts within R&D 
 The Parties
believe that the engagement of external experts in R&D should be done In accordance with the following principles: 
  

	 	•	 	 There must be a legitimate need for the services of the expert that cannot be fulfilled in-house, and the minimum number of experts needed should be used 

  

	 	•	 	 Selection of experts should be based solely on the expert’s qualifications and expertise in the subject
matter for which such expert is retained 

  

	 	•	 	 The expert’s services must be documented in a written signed agreement 

 

	 	•	 	 Compensation must be based on fair market value for the services provided 

 

	 	•	 	 Reimbursement or pre-payment for costs associated with travel, lodging,
meals and hospitality (i.e. refreshments, background music at meetings) for an expert are acceptable if permitted by all law for the location in which the services are rendered and are modest in value 

 

	 	•	 	 Experts shall not receive any gifts of any value, especially where the expert is also a healthcare professional

  
 13 

	 	•	 	 Gift includes anything of value, regardless of amount, given to show friendship, appreciation, or support,
including meals, entertainment or recreational activities (excludes fair market value for services rendered). 

  

	 	•	 	 Healthcare Professionals includes, but is not limited to, physicians, their allied health professionals, and
medical office staff. This term also applies to pharmacists and employees of pharmacy benefit managers. 

  
 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]